Featured Publications
Expression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original Research
2022
Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature
Matsumoto NP, Yuan J, Wang J, Shen Q, Chen X, Kim Y, Zuppan CW, Chang CC, Cui W, Chen D, Shi M, Gisriel SD, Chen M, Xu ML, Pan Z. Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology 2022, 35: 865-874. PMID: 35105959, DOI: 10.1038/s41379-022-01014-w.Peer-Reviewed Original ResearchConceptsMast cell sarcomaConcurrent systemic mastocytosisMast cell activation symptomsGerm cell tumorsSerum tryptase levelsMast cell tryptaseMast cell growthImmunophenotypic overlapMedian followReactive eosinophilsReview of literatureMedian ageCell sarcomaRare entitySystemic mastocytosisTherapeutic regimensTryptase levelsCell tumorsCommon siteImmunohistochemical stainingKIT D816VVariable positivityRare formPatientsActivation symptoms
2021
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute undifferentiated leukemiaWhite blood cellsLymphoblastic leukemiaAcute leukemiaBone Marrow Pathology GroupHigher white blood cellEvent-free survivalNatural killer cellsClinical outcome dataNative immune systemMore frequent expressionAUL patientsFree survivalAmbiguous lineageOverall survivalCytoplasmic CD3Leukemia groupClinical presentationHLA-DRKiller cellsPlatelet countProvisional entityCD10 expressionMyeloid leukemia
2019
Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.Peer-Reviewed Original ResearchConceptsB-cell non-Hodgkin lymphomaEBV-negative casesAggressive B-NHLPD-L1Peptide receptor radionuclide therapyAggressive B-cell lymphomasEBV-positive DLBCLEBV-positive patientsDisease-free intervalPrimary clinical outcomeYear of diagnosisEBV-positive casesReceptor radionuclide therapyExpression of SSTR2Non-Hodgkin lymphomaExpression of CD30Five yearsAvailable outcome dataB-cell lymphomaEBV negativityInitial therapyClinicopathologic characteristicsBetter prognosisCase seriesClinical outcomes
2018
Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses
Romberg N, Le Coz C, Glauzy S, Schickel JN, Trofa M, Nolan BE, Paessler M, Xu M, Lambert MP, Lakhani SA, Khokha MK, Jyonouchi S, Heimall J, Takach P, Maglione PJ, Catanzaro J, Hsu FI, Sullivan KE, Cunningham-Rundles C, Meffre E. Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal Of Allergy And Clinical Immunology 2018, 143: 258-265. PMID: 29935219, PMCID: PMC6400323, DOI: 10.1016/j.jaci.2018.06.012.Peer-Reviewed Original ResearchConceptsCommon variable immunodeficiencyVariable immunodeficiencyB cellsCommensal bacteriaIsotype-switched memory B cellsRegulatory T cell frequencyFollicular helper T cellsGC responseIsotype-switched antibodiesT cell frequenciesSubset of patientsT cell compartmentHelper T cellsPeripheral blood samplesMemory B cellsGerminal center responseB cell clonesAutoimmune cytopeniasGC hyperplasiaSerum endotoxemiaExcisional lymphAntibody responseT cellsMucosal microbiotaSomatic hypermutation frequencies
2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaYears of ageFrequent expressionOlder patientsAge cutoffMonoclonal B-cell proliferationArbitrary age cutoffsPoor performance statusGenetic featuresMore frequent expressionB cell proliferationPerformance statusYounger patientsClinicopathologic evidencePatient groupDLBCL patientsTreatment outcomesPatientsDLBCLGene expression profilingCD30Lymphoma